Af­ter BioCryst fiz­zle, a new oral HAE play­er emerges

A new play­er in the search for an oral hered­i­tary an­gioede­ma pill has re­ceived a ma­jor boost and show of con­fi­dence.

Phar­varis an­nounced $66 mil­lion in Se­ries B fi­nanc­ing for its B2 re­cep­tor an­tag­o­nist pill, near­ly tripling the fund­ing At­tune Phar­ma­ceu­ti­cals re­cent­ly re­ceived in Se­ries B for its own hered­i­tary an­gioede­ma (HAE) pill. The mon­ey will fu­el the com­pa­ny’s Phase I tri­al on its lead com­pound, PHA121, on healthy vol­un­teers. The first sub­jects have al­ready been dosed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.